health
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
TL;DR
- Both Eli Lilly and Novo Nordisk surpassed second-quarter earnings expectations and increased their full-year financial forecasts.
- Eli Lilly's stock performance improved significantly, while Novo Nordisk's shares declined, indicating a disparity in investor confidence.
- Lilly holds a larger share of the U.S. obesity and diabetes drug market (60.9%) compared to Novo Nordisk (38.8%).
- Lilly reported strong revenue growth driven by its Mounjaro and Zepbound treatments, reinforcing its market position.
- Novo Nordisk's results were supported by rebate adjustments and temporary factors, but concerns remain about its pipeline and long-term growth strategy.
- Novo's Wegovy pill revenue slightly missed analyst expectations, raising questions about its growth potential.
- Novo faced setbacks with mixed trial results for its experimental obesity drug CagriSema and a failed cardiovascular trial for ziltivekimab.
- Analysts emphasize the need for Novo Nordisk to diversify its pipeline and demonstrate a clear strategy for sustainable growth.